Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity
| Autor: | Yueqiang Jiang, JianHai Sun, RuiChao Li, Yanling Ma |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Beta-catenin biology business.industry Colorectal cancer Wnt signaling pathway Cancer medicine.disease Metastasis 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology Cancer stem cell 030220 oncology & carcinogenesis Interleukin 35 biology.protein Colon neoplasm Cancer research Medicine business |
| Zdroj: | Oncotarget. 9:11989-11998 |
| ISSN: | 1949-2553 |
| Popis: | The occurrence and development of colon cancer is closely related to inflammation. Therefore, this study was conducted a current retrospective research to study the effect of IL-35 (interleukin 35), a newly identified anti-infective factor, on colon cancer development. The expression of IL-35 in colon cancer samples and their adjacent normal mucosa by real-time PCR, ELISA (enzyme-linked immunosorbent assay). The effect of IL-35 on patient survival, colon cancer progression, and its effect on Wnt/β-catenine signaling pathway was also assessed. IL-35 is minimally expressed in colon cancer tissues but is highly expressed in adjacent normal tissues. The down-regulation of IL-35 was significantly associated with the American Cancer Joint Committee stage and overall survival of colon cancer patients. The overexpression of IL-35 in colon cancer cells inhibits cell migration, invasion, proliferation, colony formation and cancer stem cells by inhibiting beta-catenin. IL-35 inhibits colon neoplasms in mouse. Our results suggest that IL-35 has an inhibitory effect on the development of colon cancer as a novel prognostic indicator and potential therapeutic target. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|